Sateesh Kesari, MD
Advanced Heart Failure and Transplant Cardiology · Cincinnati, OHNPI 1396910824
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.6%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 37.4% of the total. 2025 is the largest year on record at $56,263, more than ten times the $827 reported in 2019. Among advanced heart failure and transplant cardiology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 388 payments — averaging $259.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$38K
- Alnylam Pharmaceuticals Inc.$30K
- Pfizer$16K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$8K
- Abbott$3K
- Abiomed$2K
- plus $4K from 27 others
Across 7 payments — averaging $3214.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$22K
- Analog Devices Inc.$500
What the payments were for
- Consulting fees$10,11010%
- Speaking & faculty fees$52,93353%
- Grants$15,00015%
- Travel & lodging$11,96612%
- Food & beverage$10,38510%
- Education$2580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 42 | $37,641 |
| Alnylam Pharmaceuticals Inc. | 34 | $30,270 |
| Pfizer | 24 | $15,565 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $7,814 |
| Abbott | 69 | $3,221 |
| Abiomed | 16 | $1,646 |
| Medtronic(2 entities) | 9 | $721 |
| Merck | 28 | $523 |
| Novartis | 36 | $473 |
| Cvrx, Inc. | 8 | $282 |
| United Therapeutics Corporation | 9 | $276 |
| Boehringer Ingelheim | 13 | $232 |
| Edwards Lifesciences | 3 | $217 |
| Actelion Pharmaceuticals US, Inc. | 11 | $203 |
| Daiichi Sankyo Inc. | 6 | $190 |
| Lexicon Pharmaceuticals, Inc. | 4 | $177 |
| AstraZeneca | 11 | $161 |
| Boston Scientific | 2 | $138 |
| Impulse Dynamics (USA) Inc. | 1 | $137 |
| Scpharmaceuticals Inc. | 8 | $137 |
| Johnson & Johnson | 7 | $102 |
| Amgen | 6 | $89 |
| Sensible Medical Innovations Inc | 1 | $70 |
| Kestra Medical Technology Services, Inc. | 3 | $69 |
| Amarin Pharma, Inc. | 3 | $57 |
| Bayer | 3 | $51 |
| Irhythm Technologies, Inc. | 1 | $39 |
| Novo Nordisk | 2 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $31 |
| Solventum Corporation | 1 | $27 |
| Inari Medical, Inc. | 1 | $25 |
| Heartflow, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$32,928
- AMVUTTRA$29,611
- LifeVest$7,212
- CARDIOMEMS$1,101
- Impella$614
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$422
- CardioMEMS HF System$275
- OPTIMIZER$275
- RESOLUTE ONYX$175
- HeartMate 3 Left Ventricular Dev$172
- Barostim Neo System$164
- Watchman$124
- Inpefa$121
- INJECTAFER$118
How this compares
$100,651 in reported general payments places this provider in the 90th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
See all advanced heart failure and transplant cardiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 94 | $771,513 |
| OpsumitMacitentan | 16 | $203,316 |
| AdempasRiociguat | 15 | $195,940 |
| Orenitram ErTreprostinil Diolamine | 15 | $107,474 |
| EntrestoSacubitril/Valsartan | 101 | $80,179 |
| JardianceEmpagliflozin | 55 | $39,049 |
| FarxigaDapagliflozin Propanediol | 49 | $33,540 |
| EliquisApixaban | 13 | $12,079 |
| Eplerenone | 15 | $1,141 |
| Metoprolol Succinate | 138 | $1,141 |
| Torsemide | 95 | $726 |
| Spironolactone | 122 | $435 |
| Atorvastatin Calcium | 21 | $337 |
| Amiodarone Hcl | 11 | $319 |
| Lisinopril | 28 | $214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $37,641 | $771,51394 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $203 | $203,31616 claims |
| BayerAdempas | $51 | $195,94015 claims |
| NovartisEntresto | $473 | $80,179101 claims |
| Boehringer IngelheimJardiance | $232 | $39,04955 claims |
| AstraZenecaFarxiga | $161 | $33,54049 claims |
| PfizerEliquis | $15,565 | $12,07913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
Other advanced heart failure and transplant cardiology in Cincinnati
- Eugene ChungCincinnati$297K
- Ankit BhatiaCincinnati$141K
- Rachel GarciaCincinnati$104K
- Sitaramesh EmaniCincinnati$87K
- Gregory EgnaczykCincinnati$62K
- Santosh MenonCincinnati$30K
- Umama GorsiCincinnati$20K
- Stephanie DunlapCincinnati$9K
- Mahyar PourriahiCincinnati$8K
- Juliane ViereckeCincinnati$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.